SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)-- Omeros ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding ...
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with ...
The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...
IgA nephropathy is the most prevalent primary glomerulonephritis worldwide, characterised by deposition of immunoglobulin A (IgA), predominantly the IgA1 subclass, within the renal mesangium. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results